84 related articles for article (PubMed ID: 1839294)
1. Differences in the induction of tumorspecific T suppressor lymphocytes among the peritoneal exudate cells in histocompatible BALB/cAnPt and BALB/cJ mouse sublines.
Lügering N; Kölsch E
Immunobiology; 1991 Dec; 184(1):106-10. PubMed ID: 1839294
[TBL] [Abstract][Full Text] [Related]
2. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
Haubeck HD; Kölsch E
Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a T suppressor cell-inducing antigenic determinant shared by ADJ-PC-5 plasmacytoma and syngeneic BALB/c spleen cells.
Kloke O; Haubeck HD; Kölsch E
Eur J Immunol; 1986 Jun; 16(6):659-64. PubMed ID: 2424769
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of in vitro and in vivo functions of a tumor-specific T suppressor cell clone from a BALB/c mouse bearing the syngeneic ADJ-PC-5 plasmacytoma.
Haubeck HD; Kölsch E
J Immunol; 1985 Dec; 135(6):4297-302. PubMed ID: 2415609
[TBL] [Abstract][Full Text] [Related]
5. Selective in-vitro activation of BALB/c T suppressor lymphocytes specific for syngeneic ADJ-PC-5 plasmacytoma cells.
Haubeck HD; Minkenberg I; Kölsch E
Clin Exp Immunol; 1988 Oct; 74(1):53-8. PubMed ID: 2975539
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cellular anti-tumour responses by tumour-specific T suppressor lymphocytes.
Haubeck HD; Stutenkemper R; Kölsch E
Clin Exp Immunol; 1988 Oct; 74(1):47-52. PubMed ID: 2975538
[TBL] [Abstract][Full Text] [Related]
7. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. IV. Tumor-specific T suppressor cells, induced at early stages of tumorigenesis, act on the induction phase of the tumor-specific cytotoxic T cell response.
Haubeck HD; Kölsch E
Immunobiology; 1986 Jul; 171(4-5):357-65. PubMed ID: 2943667
[TBL] [Abstract][Full Text] [Related]
8. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane.
Byrd LG; McDonald AH; Gold LG; Potter M
J Immunol; 1991 Nov; 147(10):3632-7. PubMed ID: 1682379
[TBL] [Abstract][Full Text] [Related]
9. Suppression of tumour-specific cytotoxic T-cell responses against the syngeneic BALB/c plasmacytoma ADJ-PC-5 by tumour-induced CD8+ regulatory T cells via IFN-gamma.
Pauels HG; Specht C; Becker C; Kölsch E
Scand J Immunol; 1996 Apr; 43(4):421-30. PubMed ID: 8668922
[TBL] [Abstract][Full Text] [Related]
10. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
Roberts LK
J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
[TBL] [Abstract][Full Text] [Related]
12. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice.
Potter M; Morrison S; Wiener F; Zhang XK; Miller FW
J Natl Cancer Inst; 1994 Jul; 86(14):1058-65. PubMed ID: 8021954
[TBL] [Abstract][Full Text] [Related]
13. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
14. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous development of plasmacytomas in a selected subline of BALB/cJ mice.
Silva S; Wang Y; Babonits M; Imreh S; Wiener F; Klein G
Eur J Cancer; 1997 Mar; 33(3):479-85. PubMed ID: 9155535
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression in plasmacytoma: induction of suppressor cells.
Chen Y; Hwang LT; Heller P
Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
[TBL] [Abstract][Full Text] [Related]
19. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells.
Liew FY; Hale C; Howard JG
J Immunol; 1982 Apr; 128(4):1917-22. PubMed ID: 6120976
[TBL] [Abstract][Full Text] [Related]
20. Suppressor T cells, distinct from "veto cells," are induced by alloantigen priming and mediate transferable suppression of cytotoxic T lymphocyte responses in vivo.
Owens T; Crispe IN
J Immunol; 1985 Nov; 135(5):2984-9. PubMed ID: 2413108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
